Managing Bone Health in Metastatic Breast Cancer

0 Views
administrator
administrator
07/03/23

Panelists discuss their preference between denosumab (Xgeva) and zoledronic acid (Zometa), which are both currently approved to help reduce the incidence of skeletal-related events (SREs) in patients with metastatic breast cancer (MBC).

To view more from this discussion, visit http://www.onclive.com/peer-ex....change/MBC-challenge

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next